Efficacy In Cancer TreatmentPetosemtamab offers clear differentiation with its dual targeting mechanism, translating into meaningful clinical activity with manageable toxicity, outperforming other EGFR-targeting agents.
Regulatory ApprovalPetosemtamab has received two Breakthrough Therapy Designations, showing strong regulatory enthusiasm for its development.
Safety And TolerabilityThe safety profile of petosemtamab is highly favorable, with manageable toxicities, enabling broader applicability in frailer or older patients.